The results showed that the expressions of inhibitory immune checkpoint, such as PD-1, CTLA-4, LAG3, TIM3 and TIGIT, in C2 were increased compared to those in C1, which hinted that HCC patients in C1 might be better responsive to immunotherapy. The gene discussed is LAG3; the disease is hepatocellular carcinoma.